The following is an excerpt.
In statehouses around the country, some of the nation’s biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, potentially cutting into the billions of dollars in savings on drug costs contemplated in the federal health care overhaul law.
View the original article here: Biotech Firms, Billions at Risk, Lobby States to Limit Generics
Additional Resources:
- “’The Signal and the Noise’ in pharmacogenomics,” The Genetic Literacy Project
